Diagnostic Tool That Identifies Patients Suitable for Keytruda Treatment Gets Latest FDA Approval
November 14th 2023PD-L1 IHC 22C3 pharmD approved to help identify patients who may be eligible to receive treatment with pembrolizumab (Keytruda) to treat gastric or gastroesophageal junction adenocarcinoma.